Anti-CTLA-4 therapy results in higher CD4 +ICOS hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 8, 2009, Pages 2729-2734

  Chen, Hong ^a   Liakou, Chrysoula I ^a   Kamat, Ashish ^a   Pettaway, Curtis ^a   Ward, John F ^a   Tang, Derek Ng ^a   Sun, Jingjing ^a   Jungbluth, Achim A ^a   Troncoso, Patricia ^a   Logothetis, Christopher ^a   Sharma, Padmanee ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Clinical trial; CTLA 4; T cells

Indexed keywords

BIOLOGICAL MARKER; CD4 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; IPILIMUMAB; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET;

ARTICLE; BLADDER CANCER; BLOOD SAMPLING; CANCER PATIENT; CANCER TISSUE; CD4+ INDUCIBLE COSTIMULATOR HI T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL MONITORING; IMMUNOTHERAPY; INCIDENTAL FINDING; MALE; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATE TUMOR; PROSTATECTOMY; PROTEIN BLOOD LEVEL; TH1 CELL; TH2 CELL; TISSUE LEVEL; TISSUE SECTION;

ANTIBODIES; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; PROSTATE; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 62449309334     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0813175106     Document Type: Article

References (35)

1. Walunas TL, et al. (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405-413.
2. Kruinmel MF, Allison JP (1995) CD28 and CTLA-4 have opposing affects on the response of T cells to stimulation. J Exp Med 182:459-465.
3. Krummel MF, Allison JP (1996) CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183:2533- 2540.
4. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-1736.
5. van Elas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte, macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355-366.
6. Hodi FS, et al. (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100:4712-4717.
7. Phan GQ, et al. (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372-8377.
8. Korman A, Yellin M, Keler T (2005) Tumor immunotherapy: Preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Investig Drugs 6:582-591.
9. Saenger YM, Wolchuk JD (2008) The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: Patient cases. Cancer Immun 8:1-7.
10. Small EJ, et al. (2007) A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13:1810-1815.
11. Attia P, et al. (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043-6053.
12. hi cellsto shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 105:14987-14992.
13. Hutloff A, et al. (1999) ICOS is an inducible T cell co-stimulator structurally and functionally related to CD28. Nature 397:263-266.
14. Yoshinaga SK, et al. (1999) T cell co-stimulation through B7RP-1 and ICOS. Nature 402:827-832.
15. Coyle AJ, et al. (2000) The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 13:95-105.
16. Dong C, et al. (2001) ICOS co-stimulatory receptor is essential for T cell activation and function. Nature 409:97-101.
17. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057-1061.
18. +T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177:7398-7405.
19. Ahmadzadeh M, et al. (2008) FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 112:4953-4960.
20. Clark RA, et al. (2008) Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med 205:2221-2234.
21. Woo EY, et al. (2002) Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168:4272-4276.
22. Ichihara F, et al. (2003) Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9:4404-4408.
23. Curiel TJ, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949.
24. +, regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538-18543.
25. Sharma P, et al. (2007) CDS tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA 104:3967-3972.
26. Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity, and cancer immunoediting. Nat Rev Immunol 6:836-848.
27. Szabo SJ, et al. (2000) A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100:655-669.
28. Murphy KM, Reiner SL (2002) The lineage decisions of helper T cells. Nat Rev Immunol 2:933-944.
29. Zheng W, Flavell RA (1997) The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89:587-596.
30. Quezada SA, Peggs KS, Curran MA, Allison JP (2006) CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116:1935-1945.
31. Sun J, et al. (2008) Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 8:9-15.
32. Hodi FS, et al. (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105:3005-3010.
33. Yuan J, et al. (2008) Cytotoxic T lymphocyte-associated antigen 4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with tumor regression. Proc Natl Acad Sci USA, 105:20410-20415.
34. Gnjatic S, et al. (2009) NY-ESO-1 DNA vaccine induces T cell responses that are suppressed by regulatory T cells. Clinical Cancer Res, in press.
35. Jungbluth AA, et al. (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92:856-860.